New Schizophrenia Drug Aims to Regenerate Lost Brain Connections

FLORENCE, ITALY – March 26, 2026 – In a presentation that could signal a turning point for psychiatric medicine, clinical-stage biopharmaceutical company Spinogenix today unveiled encouraging early data for a novel schizophrenia treatment designed not just to manage symptoms, but to rebuild lost connections in the brain. The interim results from a Phase 2 trial of the drug, tazbentetol, suggest a new path forward for a debilitating condition that affects millions worldwide.

Presented at the Schizophrenia International Research Society (SIRS) 2026 Annual Congress, the findings show that the first-in-class synaptic regenerative therapy was well-tolerated and demonstrated early potential to improve a wide range of schizophrenia symptoms. This new approach targets the underlying structural damage of the disease, a departure from decades of treatments focused primarily on symptom suppression.

The Unmet Need in Schizophrenia Care

Schizophrenia is a complex and profoundly challenging disorder, characterized by a trio of symptom domains. Positive symptoms, such as hallucinations and delusions, are the most widely recognized, but it is often the negative symptoms—including social withdrawal, lack of motivation, and an inability to feel pleasure—and cognitive deficits in memory and attention that pose the greatest barriers to a patient's quality of life and functional recovery.

For over half a century, the standard of care has revolved around antipsychotic medications that primarily act on the brain's dopamine system. While often effective at controlling positive symptoms, these treatments frequently fall short in addressing the negative and cognitive domains. This leaves a significant portion of patients struggling to maintain relationships, hold jobs, and live independently. Furthermore, an estimated one-third of individuals with schizophrenia are considered treatment-resistant, showing little to no response to available therapies.

The scientific community has increasingly focused on the role of synapse loss in the progression of schizophrenia. Synapses are the critical junctions between neurons that allow for communication, forming the bedrock of all brain function. Evidence suggests that a depletion of these connections, particularly glutamatergic synapses, is a core pathological feature of the disease, contributing to all three symptom domains. It is this fundamental problem that Spinogenix's tazbentetol aims to solve.

Early Signs of a Paradigm Shift

The data presented by Spinogenix comes from a prespecified interim analysis of its randomized, double-blind, placebo-controlled Phase 2 trial. The study enrolled 32 adults with schizophrenia, with the early results based on the first 16 participants who completed the protocol. Over a six-week period, patients received either a daily 300mg oral dose of tazbentetol or a placebo.

First and foremost, the therapy demonstrated a favorable safety profile, with no severe adverse events reported. This is a crucial hurdle for any new psychiatric medication, where side effects can often be a major barrier to adherence.

On the efficacy front, the results, while preliminary, point toward a clear therapeutic effect. Participants receiving tazbentetol showed a greater overall improvement in symptom severity compared to the placebo group. This was measured using the Positive and Negative Syndrome Scale (PANSS), a standard clinical tool. The tazbentetol group saw their total PANSS score decrease by an average of 11.1 points from baseline, compared to a 5.5-point reduction in the placebo group. This effect appeared durable, with the difference between the groups measured at Day 71, after the six-week treatment period had concluded.

Crucially, the improvements were not limited to one symptom type. The tazbentetol group showed greater reductions in both positive and negative symptom subscales compared to placebo. Perhaps most compellingly, the study incorporated electroencephalogram (EEG) measurements as an objective biomarker of brain activity. Tazbentetol treatment was associated with statistically significant improvements in schizophrenia-related abnormalities in brainwave patterns (gamma and alpha bands) in key brain regions. This neurophysiological data provides tangible evidence that the drug is having a biological effect on brain function, normalizing activity that is typically disrupted in schizophrenia.

"These results showcase the possibility for synaptic regeneration to shift our treatment approach in schizophrenia," said Dr. David Walling, PhD, Chief Clinical Officer at CenExel and the trial's Principal Investigator. "This study provides important preliminary clinical support for the role of synapse loss in the genesis of schizophrenia symptoms, with regeneration offering an intervention potentially impacting all symptom domains. I am eager to see continued promising data, including EEG analysis, as the trial progresses."

A Platform for Regeneration: Spinogenix's Broader Ambitions

The potential of tazbentetol extends far beyond schizophrenia, positioning Spinogenix at the forefront of a new wave of regenerative neurology. The company is built on the premise that restoring lost synapses can reverse dysfunction and restore health across a range of devastating neurological and neuropsychiatric conditions. This platform approach is validated by the company's concurrent clinical programs.

Tazbentetol is also being evaluated in Phase 2 trials for both Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. In its ALS program, the drug has already received Orphan Drug designation from U.S. and European regulators. In Alzheimer's, early trials have suggested the therapy can produce rapid and sustained cognitive improvements, with the FDA clearing the path for late-stage trials.

This cross-disease potential underscores the fundamental nature of the drug's mechanism. By targeting the common pathway of synaptic loss, Spinogenix is aiming to create a therapy that could have wide-ranging applications, transforming the treatment landscape for some of the most challenging diseases of the brain.

"We are encouraged by these results and the early evidence that tazbentetol can address an unmet treatment need in schizophrenia," said Dr. Stella Sarraf, CEO and Founder of Spinogenix, in a statement. "Alongside our trials assessing tazbentetol in Alzheimer's disease and ALS, this latest data adds to the indicators that a regenerative approach can make a difference to patients, refocusing treatment on the structural causes of neurological disease – synapses."

While the journey from a small, early-stage trial to an approved medicine is long and fraught with challenges, the data presented today offers a tangible source of hope. For patients, families, and clinicians who have long awaited a breakthrough, the prospect of a therapy that can rebuild the brain, not just quiet its symptoms, represents a potential new dawn in the fight against schizophrenia.